Search

Author/Creator Jamal, Rahima

1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

Authors:
Eggermont, Alexander M M; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk;...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 5(2021)
Page Start:
643
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

Authors:
Bottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Loriga...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 5(2021)
Page Start:
655
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. (3rd April 2019)

Authors:
Elkrief, Arielle; El Raichani, Layal; Richard, Corentin; Messaoudene, Meriem; Belkaid, Wiam; Malo, Julie; Belanger, Karl; Miller, Wilson; Jamal, Rahima; Letarte, Nathalie; Wong, Philip; Routy, Bertrand
Journal:
Oncoimmunology
Issue:
Volume 8:Number 4(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. (31st December 2022)

Authors:
Tonneau, Marion; Nolin-Lapalme, Alexis; Kazandjian, Suzanne; Auclin, Edouard; Panasci, Justin; Benlaifaoui, Myriam; Ponce, Mayra; Al-Saleh, Afnan; Belkaid, Wiam; Naimi, Sabrine; Mihalcioiu, Catalin; Watson, Ian; Bouin, Mickael; Miller, Wilson; Hudson, Marie; Wong, Matthew K.; Pezo, Rossanna C.; T...
Journal:
Oncoimmunology
Issue:
Volume 11:Number 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (4th November 2015)

Authors:
Lapointe, Réjean; Jamal, Rahima; van Kempen, Leon; Thebault, Pamela; Belanger, Karl; Friedmann, Jennifer; Ayoub, Jean-Pierre; Cocolakis, Eftihia; Kazemi, Shirin; Dionne, Jeanne; Lambert, Caroline; Le, Huy; Grange, Cecile; Cailhier, Jean-Francois; Spatz, Alan; Miller, Wilson
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). Issue 2 (December 2015)

Authors:
Lapointe, Réjean; Jamal, Rahima; van Kempen, Leon; Thebault, Pamela; Belanger, Karl; Friedmann, Jennifer; Ayoub, Jean-Pierre; Cocolakis, Eftihia; Kazemi, Shirin; Dionne, Jeanne; Lambert, Caroline; Le, Huy; Grange, Cecile; Cailhier, Jean-Francois; Spatz, Alan; Miller, Wilson
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Issue 1 (21st November 2017)

Authors:
Jamal, Rahima; Lapointe, Réjean; Cocolakis, Eftihia; Thébault, Paméla; Kazemi, Shirin; Friedmann, Jennifer E.; Dionne, Jeanne; Cailhier, Jean-François; Bélanger, Karl; Ayoub, Jean-Pierre; Le, Huy; Lambert, Caroline; El-Hajjar, Jida; van Kempen, Léon C.; Spatz, Alan; Miller, Wilson H.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Issue 1 (1st January 2023)

Authors:
Arance, Ana; de la Cruz-Merino, Luis; Petrella, Teresa M.; Jamal, Rahima; Ny, Lars; Carneiro, Ana; Berrocal, Alfonso; Márquez-Rodas, Ivan; Spreafico, Anna; Atkinson, Victoria; Costa Svedman, Fernanda; Mant, Andrew; Khattak, Muhammad A.; Mihalcioiu, Catalin; Jang, Sekwon; Cowey, C. Lance; Smith, A...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 1(2023)
Page Start:
75
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (July 2019)

Authors:
Eggermont, Alexander M.M.; Blank, Christian U.; Mandala, Mario; Long, Georgina V.; Atkinson, Victoria G.; Dalle, Stéphane; Haydon, Andrew; Lichinitser, Mikhail; Khattak, Adnan; Carlino, Matteo S.; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Di...
Journal:
European journal of cancer
Issue:
Volume 116(2019)
Page Start:
148
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗